COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
29 hedge funds and large institutions have $668K invested in COSCIENS Biopharma Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 7 closing their positions.
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
6% less funds holding
Funds holding: 31 → 29 (-2)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
40% less call options, than puts
Call options by funds: $200K | Put options by funds: $333K
54% less capital invested
Capital invested by funds: $1.46M → $668K (-$795K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$79.7K |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$69.2K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$28.3K |
| 4 |
Two Sigma Advisers
New York
|
+$23.4K |
| 5 |
VF
Virtu Financial
New York
|
+$19.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Natixis
Paris,
France
|
-$220K |
| 2 |
Goldman Sachs
New York
|
-$63K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$37.8K |
| 4 |
Renaissance Technologies
New York
|
-$16K |
| 5 |
LFA
Legacy Financial Advisors
Covington,
Kentucky
|
-$14K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
N
26
Natixis
Paris,
France
| – | -$220K | -2,938 | Closed |
|
|
27
Goldman Sachs
New York
| – | -$63K | -845 | Closed |
|
|
28
Simplex Trading
Chicago,
Illinois
| – | -$37.8K | -718 | Closed |
|
|
LFA
29
Legacy Financial Advisors
Covington,
Kentucky
| – | -$14K | -180 | Closed |
|
30
Squarepoint
New York
| – | -$8K | -109 | Closed |
|
31
Bank of America
Charlotte,
North Carolina
| – | -$2K | -38 | Closed |
|
32
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$632 | -12 | -75% |
|
|
MTWM
33
Masso Torrence Wealth Management
Marlton,
New Jersey
| – | +$421 | +8 | New |
|
CSCI Hedge Fund Activity: Q4 2021 in Review
29 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q4 2021, worth a combined $668K — down 54% from $1.46M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CSCI and 5 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 7 added.
The largest buyer was Citadel Advisors, adding an estimated $79.7K. The largest seller was Natixis, exiting entirely with an estimated $220K sold.
- 29 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q4 2021, down from 31 in Q3 2021.
- Funds reported $668K of COSCIENS Biopharma Inc. Common Stock stock for Q4 2021, down 54% quarter-over-quarter.
- 5 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q4 2021 and 7 closed out, a net change of -2 holders.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q4 2021 was Citadel Advisors, an estimated $79.7K added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q4 2021 was Natixis, an estimated $220K sold.
Based on aggregated 13F filings for Q4 2021.